Neuroblastoma is a malignancy of the developing sympathetic nervous system that often presents with widespread metastatic disease, resulting in survival rates of less than 50%. While mostneuroblastomas strike in a young child’s chest or abdomen in the adrenal gland or next to the spinal cord, or in the chest,the diseasecan spread to the bones (face, skull, pelvis, shoulders, arms, and legs), bone marrow, liver, lymph nodes, skin, and around the eyes (orbits). Neuroblastomais most commonly diagnosed in children before age 5 andoccurs in approximately 1 out of 100,000 children and is slightly more common in boys. It comprises 7% of all childhood cancers, but causes 10 to 15% of all childhood cancer-related deaths. Neuroblastoma usually appears as a solid tumor.

An extensive genomic study of neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease, whicmin most patients,has already spread when it is first diagnosed.

Tumors evolve in response to medicine
Contrary to expectations, the scientists found relatively few recurrent gene mutations?mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

“This research underscores the fact that tumor cells often change rapidly over time, so more effective treatments for this aggressive cancer will need to account for the dynamic nature of neuroblastoma,” said study leader John M. Maris, M.D.,director of the Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia (CHOP).

A notoriously complex disease
Neuroblastoma is notoriously complex, with a broad number of gene changes that can give rise to the disease.Maris headed the multicenter research collaborative, the TARGET (Therapeutically Applicable Research to Generate Effective Treatments; NCT01169376) initiative, which released its findings today in Nature Genetics. This largest-ever study genomic study of a childhood cancer analyzed DNA from 240 children with high-risk neuroblastomas. Using a combination of whole-exome, whole-genome and transcriptome sequencing, the study compared DNA from tumors with DNA in normal cells from the same patients.

Advertisement #3

Researchers at The Children’s Hospital of Philadelphiaand other centers previously discovered neuroblastoma-causing mutations, such as those in the ALK gene. In the subset of patients carrying this mutation, oncologists can provide effective treatments tailored to their genetic profile.

Not a menu of treatment
“A few years ago, we thought we would be able to sequence the genomes of individual patients with neuroblastoma, detect their specific cancer-causing mutations, and then select from a menu of treatments,” said Maris. The oncology researchers designed the TARGET study to perform genomic analyses of a large cohort of high-risk neuroblastoma patients, with the goal of mapping out a limited number of treatment strategies. This approach would represent a significant step forward in personalizing neuroblastoma therapy.

However, while the researchers confirmed that roughly 10% of the study’s neuroblastoma patients had ALK mutations, and found that a handful of other gene mutations each accounted for percentages in the single digits, there were relatively few recurrent mutations in somatic (non-germline) cells. “The relative paucity of recurrent mutations challenges the concept that druggable targets can be defined in each patient by DNA sequencing alone,” wrote the authors.

In the absence of frequently altered oncogenes that drive high-risk neuroblastomas, the authors concluded that most such cases may result from other changes: rare germline mutations, copy number variations and epigenetic modifications during tumor evolution.

Personalized Medicine
“Personalized medicine is more complex than we had hoped,” said Maris. “While there are successes such as those in treating patients whose tumors harbor ALK mutations, this study implies that we must think very differently about how we’ll use genomics to define treatment.” Maris added that neuroblastoma researchers may need to turn to functional genomics, learning which tumors will or won’t respond to treatments, as well as going beyond a static picture of a cancer cell with fixed genetic contents, to devising interventions to deal with dynamic tumor cells that evolve during nervous system development.

References
Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, The genetic landscape of high-risk neuroblastoma. Nature Genetics( January 20, 2013)doi:10.1038/ng.2529 [E-Pub ahead of print]

Clinical trials
NCT01169376 – Biomarkers in Young Patients With Neuroblastoma

NCT01190943 – DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01118078 – Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

NCT00896766 – Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia

Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5